Document:

Exhibit 10.14

 

Amendment
#1 to the Technology License and Services Agreement

Dated August 21, 2013

by and between

Neurotrope Bioscience, Inc., on the one hand,

and

Blanchette Rockefeller Neurosciences Institute and NRV II, LLC, 

on the other hand

 

This Amendment #1 to
the Technology License and Services Agreement (“Amendment”) is made and entered into as of August 21, 2013 (the
“Amendment Effective Date”) by and between Neurotrope BioScience, Inc. (“Neurotrope”),
on the one hand, and Blanchette Rockefeller Neurosciences Institute (“BRNI”) and NRV II, LLC (“NRV
II”), on the other hand. Neurotrope, BRNI and NRV II are sometimes referred to herein, individually, as a “Party”
or, collectively, as the “Parties.”

 

WHEREAS, pursuant
to the terms and conditions of that certain Technology License and Services Agreement (“License”), dated October
31, 2012, by and between Neurotrope, on the one hand, and BRNI and NRV II, on the other hand, BRNI and NRV II granted to Neurotrope,
effective as of the Effective Date (as defined in the License), an exclusive license in and to the Licensed Patents (as defined
in the License) and Licensed Technology (as defined in the License); and

 

WHEREAS, each
of the Parties agrees the Neurotrope Board of Directors should resolve certain disputes relating to Services and that BRNI shall
not commercially unreasonably withhold consent to Neurotrope engaging a Person other than BRNI to provide research or development
services or other related scientific assistance and support services;

 

WHEREAS, the
Parties desire to amend the License by this Amendment, including to provide for such agreement.

 

NOW, THEREFORE,
in consideration of the mutual promises and covenants set forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows.

 

1.                 
Terms used in this Amendment with initial capital letters, but not defined in this Amendment, shall have their respective
meanings set forth in the License.

 

2.                 
Section 3.1 of the License shall be deemed to be amended to include the following sentence:

 

In the event of a dispute regarding
whether BRNI is able to provide any Services and no Third Party is clearly in a superior position to provide services identical
or similar to such Services, the Board of Directors of Neurotrope shall resolve any such disputes.

 

3.                 
The first sentence of Section 3.2 of the License shall be deemed to be replaced in its entirety with the following:

 

    	 

    	 

    

 

Neurotrope shall not engage any
Person other than BRNI to provide any research or development services or other related scientific assistance and support services
(including pre-clinical or clinical activities or trials), including any services identical or similar to the Services, without
BRNI’s prior written consent which shall not be commercially unreasonably withheld.

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
each of the Parties hereto, by its duly authorized representative, has caused this Amendment to be executed as of the Amendment
Effective Date.

 

	 	NEUROTROPE BIOSCIENCE, INC.
	 	 
	 	
        By:/s/ Jim New

        (Signature)

	 	 
	 	Name:Jim New
	 	 
	 	Title:CEO
	 	 
	 	BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE
	 	 
	 	
        By: /s/ William Singer

        (Signature)

	 	 
	 	Name:William Singer
	 	 
	 	Title:President
	 	 
	 	NRV II, LLC
	 	 
	 	
        By:/s/ William Singer

        (Signature)

	 	 
	 	Name:William Singer, Director of Neuroscience Research Ventures, Inc.
	 	 
	 	Title:Managing Member of NRV II, LLCExhibit 10.15

 

 

AMENDED AND RESTATED STOCKHOLDERS AGREEMENT

 

THIS AMENDED AND RESTATED
STOCKHOLDERS AGREEMENT (this “Agreement”) is made and entered into as of August 23, 2013 by and among Neurotrope,
Inc., a Nevada corporation (the “Company”), Neurosciences Research Ventures, Inc., a West Virginia corporation
(“NRV”), Dan Alkon (“Alkon”) and each of the Persons listed on the Schedule of Abeles
Group Stockholders attached hereto (each, an “Abeles Stockholder” and, collectively, the “Abeles
Stockholders”). NRV, Alkon and the Abeles Stockholders are collectively referred to herein as the “Stockholders”
and individually as a “Stockholder.” The Company and the Stockholders are sometimes collectively referred to
herein as the “Parties” and individually as a “Party.” Capitalized terms used herein and
not otherwise defined herein have the meanings given to such terms in ‎Section 7.

 

WHEREAS, Neurotrope BioScience,
Inc., a Delaware corporation (“Neurotrope”) and each of NRV, Alkon and the Abeles Stockholders are parties to
a Stock Purchase Agreement, each dated as of October 31, 2012, as amended (the “Founder Purchase Agreements”),
pursuant to which, among other things, each of NRV, Alkon and the Abeles Stockholders purchased shares of common stock of Neurotrope,
par value $0.01 per share (the “Neurotrope Common Stock”), all on the terms and subject to the conditions set
forth in their respective Founder Purchase Agreements;

 

WHEREAS, the Stockholders,
Neurotrope, Blanchette Rockefeller Neurosciences Institute, a not-for-profit institution organized and existing under the laws
of the state of West Virginia ("BRNI") and NRV II, LLC, a Delaware limited liability company (“NRV II”)
are parties to the Stockholders Agreement dated October 31, 2012 (the "Prior Agreement");

 

WHEREAS, Neurotrope has
entered into a merger agreement, dated August 23, 2013 (the "Merger Agreement") with a newly formed subsidiary
of the Company ("MergerCo"), pursuant to which MergerCo shall merge with and into Neurotrope, with Neurotrope
remaining as the surviving entity after the merger and a wholly owned subsidiary of the Company (the “Merger”);

 

WHEREAS, pursuant to
the Merger, the Stockholders will receive common stock of the Company ("Common Stock"), in exchange for their
shares of Neurotrope Common Stock; and

 

WHEREAS, the Company
and the parties to the Prior Agreement desire to amend and restate the Prior Agreement in its entirety, effective as of the Effective
Time (as defined in the Merger Agreement) to (a) remove NRV II and BRNI as parties to the Agreement and (b) set forth certain agreements
among the Company and the Stockholders with respect to the governance of the Company and the disposition of the Common Stock.

 

NOW, THEREFORE, in consideration
of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties hereby agree that, as of the Effective Time, the Prior Agreement shall be amended and restated in its
entirety as follows:

 

    	 

    	 

    

Section
1.     Board of Directors.

 

1A.          
     Board Composition. From and after the date hereof and until the provisions of this ‎Section 1
cease to be effective or are amended in accordance with the provisions of ‎Section 9 hereof,
each holder of Stockholder Shares shall vote all of the securities of the Company that such holder beneficially owns (as such
term is defined in SEC Rule 13d-3) and shall take all other necessary or desirable actions within his, her or its control,
whether in his, her or its capacity as a stockholder, director, member of a board committee or officer of the Company or
otherwise, and including attendance at meetings in person or by proxy for purposes of obtaining a quorum and execution of
written consents in lieu of meetings (and shall refrain from taking any action the purpose of which is to frustrate the
purposes of this Section 1A), and the Company shall take all necessary or desirable actions within its control,
including calling special board and stockholder meetings, so that:

 

(i)                
the authorized number of directors shall be established and maintained at seven (7), with six (6) directors elected
by the holders of a majority of the issued and outstanding Common Stock, voting as a separate class (each, a "Common Director")
and one (1) director elected by the holders of a majority of the issued and outstanding shares of Series A convertible preferred
stock of the Company (the "Series A Preferred Stock"), voting as a separate class on an as-converted basis;

 

(ii)              
the following five (5) persons shall be nominated and elected to the Board as Common Directors:

 

(a)               
two (2) representatives designated by NRV (each, an “NRV Designee”), who initially shall
be William S. Singer and Ralph Bean;

 

(b)              
two (2) representatives designated by the Majority Abeles Stockholders (each, an “Abeles Designee”),
who initially shall be Dr. John Abeles and Dr. Jim New; and

 

(c)               
one (1) independent representative designated by the Board (the "Neurotrope Designee"), which designee
has not been determined as of the date of this Agreement; and

 

(iii)            
subject to the provisions of applicable law, no NRV Designee, Abeles Designee or Neurotrope Designee shall be removed
from the Board unless such removal is requested in writing by the party that designated such designee.

 

1B.               
Expense Reimbursement. The Company shall pay the reasonable out-of-pocket expenses (including travel expenses)
incurred by each Director in connection with attending the meetings of the Board, any Subsidiary Board and any committee thereof
on which such Director in then serving.

 

1C.               
Termination. Subject to Section 21, the provisions of this Section 1 shall terminate
automatically and shall be of no further force and effect upon the consummation of a Qualified Public Offering. For the avoidance
of doubt, the Merger shall not be deemed to be a Qualified Public Offering.

 

    	- 2 -

    	 

    

Section
2.     Irrevocable Proxy; Conflicting Agreements.

 

2A.               
Irrevocable Proxy. In order to secure each holder’s obligation to vote his, her or its Stockholder Shares
and other voting securities of the Company in accordance with the provisions of Section l, Section 4D and
Section 24, each Stockholder hereby appoints NRV as such Stockholder’s true and lawful proxy and attorney in fact,
with full power of substitution, to vote all of such holder’s Stockholder Shares and other voting securities of the Company
for the election and/or removal of Directors and all such other matters as expressly provided for in Section l, Section 4D
and, with respect to the Abeles Stockholders only, Section 24. NRV may exercise the irrevocable proxy granted to it hereunder
at any time such holder fails to comply with the provisions of Section 1, Section 4D or Section 24 of this
Agreement. The proxies and powers granted by each holder pursuant to this Section 2A are coupled with an interest and
are given to secure the performance of such holder’s obligations under this Agreement. Such proxies and powers will be irrevocable
for the term of this Agreement and will survive the death, incompetence or disability of such holder and the respective holders
of their Stockholder Shares. Subject to Section 21, the proxy granted hereunder shall terminate automatically and shall
be of no further force and effect upon the consummation of a Qualified Public Offering; provided that the proxy granted hereunder
by the Abeles Stockholders with respect to voting obligations set forth in Section 24 shall expire upon the first to occur
of (a) the completion of the Subsequent Financing and (b) the consummation of a Qualified Public Offering.

 

2B.               
Representations and Warranties; Conflicting Agreements. Each Stockholder represents that (i) this Agreement
has been duly authorized, executed and delivered by such Stockholder and constitutes the valid and binding obligation of such Stockholder,
enforceable in accordance with its terms, and (ii) such Stockholder has not granted and is not a party to any proxy, voting
trust or other agreement that is inconsistent with or conflicts with the provisions of this Agreement. No holder of Stockholder
Shares shall grant any proxy or become party to any voting trust or other agreement that is inconsistent with or conflicts with
the provisions of this Agreement.

 

Section
3.     [Reserved].

 

Section
4.     Transfer of Stockholder Shares.

 

4A.               
Required Consent. No Stockholder shall Transfer any interest in any Stockholder Shares without first obtaining
the prior written consent of both the Board, which consent may be withheld in the Board’s sole discretion, and NRV, which
consent may be withheld in NRV’s sole discretion (the “Required Consent”), except that any Stockholder
may Transfer Stockholder Shares (i) pursuant to Section 4C (but not as a Transferring Stockholder unless in compliance
therewith) or Section 4D, (ii) pursuant to any forfeiture or repurchase provisions set forth in any applicable
Employment Agreement and/or Equity Agreement, (iii) in a Public Sale and (iv) to their respective Permitted Transferees, provided
that, in the case of any Transfer by a Stockholder under this clause (iv), such Stockholder retains voting control of such
Stockholder Shares (collectively, the “Exempt Transfers”). The restrictions contained in this Section 4A
and Sections 4B, 4C and 4D shall terminate automatically and shall be of no further force and effect
upon the consummation of a Qualified Public Offering. If any Person acquires Stockholder Shares pursuant to clause (iv) above as
a Permitted Transferee by virtue of (y) such Person’s qualification as a member of a transferor’s Family Group
under clauses (ii) or (iii) of the definition of Family Group or (z) such Person’s qualification as an Affiliate of a transferor,
and such Person shall, at any time, cease to be either a member of such transferor’s Family Group or an Affiliate of such
transferor (as applicable), then such Person shall be required to Transfer such Person’s Stockholder Shares to a Person that
does qualify at the time of such required Transfer as either a member of the original transferor’s Family Group or as an
Affiliate of the original transferor.

 

    	- 3 -

    	 

    

4B.                
First Refusal Rights.

 

(i)                
Offer. Upon obtaining the Required Consent and subject to compliance with all other provisions of this Agreement,
and after obtaining a bona fide written offer to acquire any Stockholder Shares (except pursuant to an Exempt Transfer), at least
60 days (or such shorter period as may be determined by the Board and NRV) prior to any Transfer of any Stockholder Shares
(except pursuant to an Exempt Transfer), any Stockholder desiring to make such Transfer (the “RFR Transferring Stockholder”)
shall deliver a written notice (the “Offer Notice”) to the Company and each other holder of Stockholder Shares,
specifying in reasonable detail the identity, background and ownership (if applicable) of the prospective Transferee(s), the number
and class of Stockholder Shares to be Transferred (the “Offered Shares”) and the price and other terms and conditions
of the proposed Transfer. The Offer Notice shall constitute a binding offer to sell the subject shares on such terms and conditions.
The RFR Transferring Stockholder shall not consummate such proposed Transfer until at least 60 days (or such shorter period as
determined by the Board and NRV) after the delivery of the Offer Notice, unless the parties to the Transfer have been finally determined
pursuant to this Section 4B and Section 4C prior to the expiration of such 60-day (or shorter) period (the
date of the first to occur of (y) the expiration of such 60-day period (or such shorter period as determined by the Board
and NRV) after delivery of the Offer Notice or (z) such final determination is referred to herein as the “Authorization
Date”).

 

(ii)              
Company Election. The Company may elect to purchase all or any portion of
the Offered Shares at the price and on the other terms set forth in the Offer Notice, by delivering written notice of such election
to the RFR Transferring Stockholder and each holder of Stockholder Shares within 20 days after delivery of the Offer Notice.

 

(iii)            
Stockholder Election. If the Company does not elect to purchase all of the Offered Shares, then each holder
of Stockholder Shares may elect to purchase all or any portion up to such holder’s pro rata share
(based on the number of shares of Common Stock held by such holder on a fully-diluted, as-if-converted
basis) of the remaining Offered Shares at the price and on the other terms set forth in the Offer Notice, by delivering
written notice of such election to the RFR Transferring Stockholder and the Company within 30 days after delivery of the Offer
Notice. Any Offered Shares not elected to be purchased by the end of such 30-day period shall during
the immediately following 5-day period be reoffered by the RFR Transferring Stockholder to the holders of Stockholder Shares
who have elected to purchase their pro rata share of the remaining Offered Shares and, if such Persons
collectively indicate interest within said 5-day period in acquiring additional Offered Shares in an amount in excess of the aggregate
amount of Offered Shares remaining, such remaining Offered Shares will be allocated among such Persons pro rata in accordance with
their respective holdings of Common Stock on a fully-diluted, as-if-converted basis.

 

    	- 4 -

    	 

    

(iv)            
Closing. If the Company and/or the holders of Stockholder
Shares have elected to purchase all or any portion of the Offered Shares from the RFR Transferring Stockholder, such purchase
shall be consummated as soon as practicable after the delivery of the election notice(s) to the RFR Transferring Stockholder, but
in any event within 30 days after the Authorization Date. Notwithstanding any other provision hereof, in the event that the sale
price, or any portion thereof, for the Offered Shares is not payable in the form of cash at closing or cash payable on a deferred
basis (such as pursuant to promissory notes issued by the prospective Transferee(s) described in the Offer Notice), the Company
and/or each holder of Stockholder Shares electing to purchase
Offered Shares pursuant to this Section 4B shall be required to pay only such portion, if any, of the sale price described
in the Offer Notice as consists of such cash consideration, and delivery of such consideration to the RFR Transferring Stockholder
shall be payment in full for such Offered Shares.

 

(v)              
No Election. If the Company and the holders of Stockholder
Shares do not elect, in the aggregate, to purchase all of the Offered Shares from the RFR Transferring Stockholder, then,
subject to compliance with Section 4C below, the RFR Transferring Stockholder shall have the right, within the 60 days
following the Authorization Date, to Transfer such Offered Shares which the Company and the holders
of Stockholder Shares have not elected to purchase to the Transferee(s) specified in the Offer
Notice (less the number of Offered Shares acquired by the Company and the holders of Stockholder Shares)
in the amounts specified in the Offer Notice at a price not less than the price per share specified in the Offer Notice and on
other terms no more favorable to the Transferee(s) thereof than specified in the Offer Notice. Any Offered Shares not so Transferred
within such 60-day period shall be reoffered to the Company and the holders of Stockholder
Shares pursuant to this Section 4B prior to any subsequent Transfer.

 

4C.               
Tag-Along Rights.

 

(i)                
Participation Right. At least 20 days prior to any Transfer of any Stockholder Shares by any Stockholder (other
than an Exempt Transfer), each Stockholder making such Transfer (the “Transferring Stockholder”)
shall deliver a written notice (the “Sale Notice”) to the Company and the other holders of Stockholder Shares
who have not elected to purchase Offered Shares pursuant to Section 4B,, specifying in reasonable detail the identity of
the prospective Transferee(s), the number and class of Stockholder Shares to be Transferred and the terms and conditions of the
Transfer (including the price which will reflect each Stockholder Share’s Pro Rata Share). Such other holders of Stockholder
Shares may elect to participate in the contemplated Transfer by delivering written notice to the Transferring Stockholder within
15 days after delivery of the Sale Notice; provided that if the Transferring Stockholder is selling a strip
of securities, then any participating Stockholder shall be required to sell the same strip of securities (on the same terms and
conditions and in the same proportion) that the Transferring Stockholder is so Transferring, to the extent possible. Such participation
shall be based upon the Pro Rata Share represented by the Stockholder Shares requested to be included by each such holder relative
to the Pro Rata Share of all Stockholder Shares held by the holders participating in such Transfer (including the Transferring
Stockholder). If no other holder of Stockholder Shares has elected to participate in the contemplated Transfer (through notice
to such effect or expiration of the 15-day period after delivery of the Sale Notice), then the Transferring Stockholder may Transfer
the Stockholder Shares specified in the Sale Notice at a price and on terms no more favorable to the Transferee(s) thereof than
specified in the Sale Notice, during the 60-day period immediately following the Authorization Date. Any Transferring Stockholder’s
Stockholder Shares not Transferred within such 60-day period shall be subject to the provisions of this Section 4C
upon subsequent Transfer.

 

    	- 5 -

    	 

    

(ii)              
Participation Procedure; Conditions. With respect to any Transfer subject to Section 4C(i), each
Transferring Stockholder shall use his, her or its reasonable best efforts to obtain the agreement of the prospective Transferee(s)
to the participation of the other holders of Stockholder Shares who have elected to participate in any contemplated Transfer, and
no Transferring Stockholder shall Transfer any of its Stockholder Shares to any prospective Transferee if such prospective Transferee(s)
declines to allow the participation of such other holders on the terms provided herein, unless in connection with such Transfer
one or more of the Transferring Stockholders or their Affiliates purchase (on the same terms and conditions on which such Stockholder
Shares were to be sold to the Transferee(s)) the number and class of Stockholder Shares from each such other holder which such
other holder would have been entitled to sell pursuant to Section 4C(i). Each Person Transferring Stockholder Shares
pursuant to this Section 4C shall pay its share (on a Pro Rata Basis) of the expenses incurred by the Transferring
Stockholder in connection with such Transfer and shall be obligated to join on a Pro Rata Basis in any indemnification or other
obligations that the Transferring Stockholder agrees to provide in connection with such Transfer (other than any such obligations
that relate specifically to a particular holder such as indemnification with respect to representations and warranties given by
a Stockholder regarding such Stockholder’s title to and ownership of Stockholder Shares which shall be given on an individual
basis); provided that unless a prospective Transferee permits a Stockholder to give a guarantee, letter of credit
or other mechanism (which shall be dealt with on an individual basis), any escrow of proceeds of any such transaction shall be
withheld on a Pro Rata Basis among all participating holders of Stockholder Shares.

 

4D.               
Approved Sale; Drag-Along Obligations.

 

(i)                
If at any time the Board approves a Fundamental Change or Change in Ownership (as applicable, an “Approved
Sale”), each holder of Stockholder Shares and each Person that retains voting control of any Stockholder Shares Transferred
in accordance with Section 4A (each, a “Holder”) shall (and shall cause any Director(s) designated
by it to) take and otherwise facilitate the following actions:

 

(a)               
vote for (whether at a meeting of the Company’s stockholders or by written consent), consent to and raise no
objections against, and not otherwise impede or delay, such Approved Sale;

 

(b)              
if the Approved Sale is structured as a (A) merger or consolidation, such Holder shall waive any dissenters
rights, appraisal rights or similar rights in connection with such merger or consolidation or (B) sale of capital stock or
other equity securities, such Holder shall agree to sell or dispose of (and shall sell and dispose of) all of such Holder’s
Stockholder Shares and other securities of the Company on the terms and conditions approved by the Board; and

 

    	- 6 -

    	 

    

(c)               
take all necessary or desirable actions (in such Holder’s capacity as a stockholder of the Company or otherwise)
in connection with the consummation of the Approved Sale as reasonably requested by the Board (including
any applicable purchase agreement, stockholders agreement and/or indemnification and/or contribution agreement and, only in the
case of Holders who are Executive Stockholders and any other Holders that are Executives or Permitted Transferees thereof,
executing and delivering non-competition and non-solicitation agreements and the like whether or not executed by non-Executive
Holders).

 

(ii)              
The obligations of the Holders with respect to the Approved Sale are subject to the satisfaction of the conditions
that (and the Company shall take such actions as are necessary so that) each holder of Stockholder Shares
shall receive in exchange for the Stockholder Shares held by such Holder the same portion of the aggregate consideration (however
described or allocated) from such transaction that such holder of Stockholder Shares would have received if such aggregate consideration
had been distributed by the Company pursuant to a liquidation, dissolution and winding up of the Company in accordance with the
provisions of the Certificate of Incorporation.

 

(iii)            
Notwithstanding anything herein to the contrary, the Holders shall be severally obligated to join on a Pro Rata Basis
(as if such indemnification obligations reduced the aggregate proceeds available for distribution or payment to the holders of
Stockholder Shares in such Approved Sale) in any indemnification obligations the Board agreed to in connection with such Approved
Sale; provided that no Holder shall be obligated to enter into indemnification obligations with respect to matters
particular to any other Holder or such other Holder’s (or its Permitted Transferee’s) Stockholder Shares and no Holder
shall be required to agree to indemnification obligations in excess of the proceeds received by such Holder (or its Permitted Transferee)
in such Approved Sale; provided further that unless a prospective Transferee permits a Holder to give a guarantee,
letter of credit or other mechanism (which shall be dealt with on an individual basis), any escrow of proceeds of any such transaction
shall be withheld on a Pro Rata Basis among all Holders (as if such escrow reduced the aggregate proceeds available for distribution
or payment to the holders of Stockholder Shares in such Approved Sale). Each Holder shall pay its share determined on a Pro Rata
Basis (as if such expenses reduced the aggregate proceeds available for distribution or payment to the holders of Stockholder Shares
in such Approved Sale) of the expenses incurred by the Company pursuant to an Approved Sale to the extent such expenses are incurred
for the benefit of all Holders. Expenses incurred by any Holder on its his, her or its own behalf (including the fees and disbursements
of counsel, advisors and other Persons retained by such Holder in connection with the Approved Sale) will not be considered costs
incurred for the benefit of all Holders and, to the extent not paid by the Company, will be the responsibility of such Holder.
Each Holder shall enter into any indemnification, contribution or stockholder/seller representative
agreement requested by the Board to ensure compliance with this Section 4D and hereby consents and agrees to abide
by the customary provisions of any merger or similar agreement providing for a stockholder/seller
representative. Each Holder shall enter into any other agreement that the Board approves and (other
than non-competition and non-solicitation agreements to be entered into by Holders who are also employees of the Company
or any of its Subsidiaries) enter into such agreements on the same terms and conditions (other than
as differences in such terms and conditions might result from holdings of different classes of Stockholder Shares). Without limiting
the immediately prior sentence, each Holder shall enter into any indemnification, contribution or stockholder/seller representative
agreement requested by the Board to ensure compliance with this Section 4D(iii), and the provisions of this Section 4D(iii)
requiring several liability shall be deemed complied with if such requirement is addressed through such agreement, even if the
purchase and sale agreement or merger agreement related to the Approved Sale provides for joint and several liability.

 

    	- 7 -

    	 

    

(iv)            
If the Company or any of its Subsidiaries enters into any negotiation or transaction for which Rule 506 (or any similar
rule then in effect) promulgated by the Securities and Exchange Commission may be available with respect to such negotiation or
transaction (including a merger, consolidation or other reorganization), each Excluded Stockholder shall, at the request of the
Company, appoint a “purchaser representative” (as such term is defined in Rule 501 promulgated under the Securities
Act) designated by the Company. If any Holder so appoints such purchaser representative, the Company shall pay the fees of such
purchaser representative. However, if any Holder declines to appoint the purchaser representative designated by the Company, such
Holder shall appoint another purchaser representative (reasonably acceptable to the Company), and such Holder shall be responsible
for the fees of the purchaser representative so appointed.

 

4E.                
Additional Restrictions on Transfer.

 

(i)                
Execution of Counterpart. Except in connection with an Approved Sale or a Public Sale, each Transferee of
Stockholder Shares or other interests in the Company (including any Permitted Transferee or otherwise in connection with an Exempt
Transfer other than a Public Sale) shall, as a condition precedent to such Transfer, execute and deliver to the Company a counterpart
to this Agreement substantially in the form of Exhibit A attached hereto, pursuant to which such Transferee shall agree
to be bound by the provisions of this Agreement. Notwithstanding the foregoing, any Person who acquires in any manner whatsoever,
other than in connection with an Approved Sale or a Public Sale, any Stockholder Shares or other interest in the Company, irrespective
of whether such Person has accepted and adopted in writing the terms and provisions of this Agreement, shall be deemed by the acceptance
of the benefits of the acquisition thereof to have agreed to be subject to and bound by all of the terms and conditions of this
Agreement that any predecessor in such Stockholder Shares or other interest in the Company of such Person was subject to or by
which such predecessor was bound.

 

(ii)              
Notice. In connection with the Transfer of any Stockholder Shares, the holder
of such Stockholder Shares will deliver written notice to the Company describing in reasonable detail the Transfer or proposed
Transfer.

 

    	- 8 -

    	 

    

(iii)            
Legal Opinion. No Transfer of Stockholder Shares or other interest in the Company may be made unless such
Transfer would not violate any federal securities laws applicable to the Company or the interest to be Transferred. Upon reasonable
request of the Company, the proposing Transferor shall deliver to the Company prior to the date of the Transfer an opinion of counsel
reasonably acceptable to the Company as to the foregoing.

 

(iv)            
No Avoidance of Provisions. No holder of Stockholder Shares shall directly or indirectly (i) permit the
Transfer of all or any portion of the direct or indirect equity or beneficial interest in such holder or (ii) otherwise seek
to avoid the provisions of this Agreement by issuing, or permitting the issuance of, any direct or indirect equity or beneficial
interest in such holder, in any such case in a manner which would fail to comply with this Section 4 if such holder
had Transferred Stockholder Shares directly.

 

4F.             
Legend. Each certificate evidencing Stockholder Shares and each certificate issued in exchange for or upon
the Transfer of any Stockholder Shares (if such shares remain Stockholder Shares as defined herein after such Transfer) shall be
stamped or otherwise imprinted with a legend in substantially the following form:

 

THE SECURITIES REPRESENTED
BY THIS CERTIFICATE WERE ORIGINALLY ISSUED ON AUGUST 23, 2013 HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS (“STATE ACTS”) AND MAY NOT BE SOLD, ASSIGNED,
PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR STATE ACTS
OR AN EXEMPTION FROM REGISTRATION THEREUNDER.

 

THE TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE
CONDITIONS SPECIFIED IN AN AMENDED AND RESTATED STOCKHOLDERS AGREEMENT, DATED AS OF AUGUST 23, 2013 BY AND AMONG THE ISSUER OF
SUCH SECURITIES (THE “COMPANY”) AND ITS STOCKHOLDERS (THE “STOCKHOLDERS AGREEMENT”). THE
SECURITIES REPRESENTED BY THIS CERTIFICATE MAY ALSO BE SUBJECT TO ADDITIONAL TRANSFER RESTRICTIONS, CERTAIN VESTING PROVISIONS,
REPURCHASE OPTIONS, OFFSET RIGHTS AND FORFEITURE PROVISIONS SET FORTH IN THE STOCKHOLDERS AGREEMENT AND/OR A SEPARATE AGREEMENT
WITH THE INITIAL HOLDER HEREOF. A COPY OF SUCH CONDITIONS, REPURCHASE OPTIONS AND FORFEITURE PROVISIONS SHALL BE FURNISHED BY
THE COMPANY TO THE HOLDER HEREOF UPON WRITTEN REQUEST AND WITHOUT CHARGE.

 

The Company shall imprint such legend on
certificates evidencing Stockholder Shares outstanding prior to the date hereof. The legend set forth above shall be removed from
the certificates evidencing any shares which cease to be Stockholder Shares. If a Stockholder delivers to the Company an opinion
of counsel, satisfactory in form and substance to the Board (which opinion may be waived by the Board), that no subsequent Transfer
of Stockholder Shares will require registration under the Securities Act, the Company will promptly upon such contemplated Transfer
deliver new certificates evidencing such Stockholder Shares which do not bear the portion of the restrictive legend relating to
the Securities Act set forth in this Section 4F.

 

    	- 9 -

    	 

    

4G.               
Public Offering. In the event that the Board approves a Public Offering and such Public Offering is an underwritten
offering and the managing underwriters advise the Company in writing that in their opinion the capital structure of the Company
shall adversely affect the marketability of the offering, or in the event otherwise determined by the Board, then each Holder shall
consent to and vote for a recapitalization, reorganization and/or exchange of the capital of the Company into securities that the
managing underwriters and the Board find acceptable and shall take all necessary or desirable actions in connection with the consummation
of the recapitalization, reorganization and/or exchange (including, without limitation, through the formation of a new parent holding
company, as a result of which the Company would be a Subsidiary of such newly formed entity); provided, however,
that the Company shall reimburse each Holder for the reasonable expenses incurred by such Holder in taking such actions.

 

4H.              
Transfer Fees and Expenses. Except as provided in Sections 4B, 4C or 4C, the Transferor
and Transferee of any Stockholder Shares or other interest in the Company shall be jointly and severally obligated to reimburse
the Company for all reasonable expenses (including attorneys’ fees and expenses) of any Transfer or proposed Transfer, whether
or not consummated.

 

4I.                 
Void Transfers. Any Transfer of any Stockholder Shares or other interest in the Company in contravention of
this Agreement (including, without limitation, the failure of the Transferee to execute a counterpart to this Agreement) shall
be void and of no effect and shall not bind or be recognized by the Company or any other Person.

 

Section
5.    Holdback Agreement. No Stockholder shall (A) offer, sell, contract to sell, pledge or otherwise dispose
of (including sales pursuant to Rule 144), directly or indirectly, any equity securities of the Company or any of its Subsidiaries,
or any securities convertible into or exchangeable or exercisable for such securities (including equity securities of the Company
or any of its Subsidiaries that may be deemed to be owned beneficially by such holder in accordance with the rules and regulations
of the Securities and Exchange Commission), (B) enter into a transaction which would have the same effect as described in
clause (A) above, (C) enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic
consequences or ownership of any securities referred to in clause (A) above, whether such transaction is to be settled by delivery
of such securities, in cash or otherwise (each of (A), (B) and (C) above, a “Sale Transaction”), or (D) publicly
disclose the intention to enter into any Sale Transaction, in any such case during the seven days prior to and the 90-day period
beginning on the effective date of any underwritten registration (the “Holdback Period”), except as part of
any such underwritten registration, unless the underwriters managing the registered public offering otherwise agree in writing.
If requested by the managing underwriters, each Stockholder agrees to execute customary lock-up agreements consistent with the
foregoing obligations with the managing underwriter(s) of an underwritten offering with a duration not to exceed the Holdback Period,
as applicable. If (i) the Company issues an earnings release or discloses other material information or a material event relating
to the Company occurs during the last 17 days of the Holdback Period (as applicable) or (ii) prior to the expiration of the
Holdback Period (as applicable), the Company announces that it will release earnings results during the 16-day period beginning
upon the expiration of such period, then to the extent necessary for a managing or co-managing underwriter of a registered offering
required hereunder to comply with FINRA Rule 2711(f)(4), the Holdback Period (as applicable) will be extended until 18 days after
the earnings release or disclosure of other material information or the occurrence of the material event, as the case may be (a
“Holdback Extension”). The Company may impose stop-transfer instructions with respect to the shares of its Common
Stock (or other securities) subject to the foregoing restriction during any Holdback Period or any period of Holdback Extension.

 

    	- 10 -

    	 

    

Section
6.     [Reserved].

 

Section
7.     Definitions.

 

“Affiliate”
of any particular Person shall mean any other Person controlling, controlled by or under common control with such particular Person,
where “control” means the possession, directly or indirectly, of the power to direct the management and policies of
a Person whether through the ownership of voting securities, contract or otherwise, and such “control” will be conclusively
presumed if any Person owns ten percent (10%) or more of the voting capital stock or other ownership interests, directly or indirectly,
of any other Person.

 

“Certificate
of Incorporation” shall mean the Certificate of Incorporation of Neurotrope, Inc.

 

“Change in Ownership”
means any sale, transfer or issuance or series of sales, transfers and/or issuances of shares of the Company’s capital stock
by the Company or any holders thereof which results in the holders of Common Stock and Series A Preferred Stock as of the effective
time of the Merger (and after giving effect to the Merger) ceasing to own more than 50% of the Company’s Common Stock (assuming
conversion of the Series A Preferred Stock) immediately after such sale, transfer or issuance or series of sales, transfers and/or
issuances.

 

“Director”
shall mean an individual serving as a member of the Board.

 

“Employment
Agreement” shall mean any employment agreement, consulting agreement, confidentiality
agreement, non-competition agreement, non-solicitation agreement or any similar agreement between an Executive, on the one hand,
and the Company and/or any of its Subsidiaries, on the other hand, each as amended, modified and/or waived from time to time.

 

“Equity Agreement”
shall mean any document, instrument or agreement entered into in connection with any issuance
of Stockholder Shares effecting the purchase of such Stockholder Shares and evidencing the terms and conditions thereof (including,
without limitation, transfer restrictions, vesting and forfeiture or buyback provisions).

 

“Equity Incentive
Plan” shall mean the Neurotrope, Inc. 2013 Equity Incentive Plan.

 

    	- 11 -

    	 

    

“Equity Securities”
shall mean (i) capital stock (including the Series A Preferred Stock and the Common
Stock) of, membership interests, partnership interests or other equity interests in, the Company or any of its Subsidiaries (including,
without limitation, other classes, groups or series thereof having such relative rights, powers, and/or obligations as may from
time to time be established by the Board, including rights, powers, and/or duties different from, senior to or more favorable than
existing classes, groups and series of units, stock and other equity interests in the Company or any of its Subsidiaries, and including,
without limitation, any so-called “profits interests”); (ii) obligations, evidences of indebtedness or other debt
or equity securities or interests convertible or exchangeable into such equity interests in the Company or any of its Subsidiaries;
and (iii) warrants, options or other rights to purchase or otherwise acquire such equity interests in the Company or any of
its Subsidiaries.

 

“Executive”
shall mean any Person rendering services to the Company or any of its Subsidiaries as an officer,
director, manager, employee, advisor, independent contractor or consultant.

 

“Executive Stockholder”
shall mean any Stockholder who is or was an Executive, or any Stockholder which has any stockholders,
partners, members or other owners who are or were Executives.

 

“Fair Market
Value” shall mean (i) with respect to cash, the amount thereof; (ii) with
respect to securities, their market price as determined in good faith by the Board; and (iii) with respect to any consideration
other than cash and securities, its fair value determined on the basis of an orderly, arm’s length sale (structured to produce
the highest price for such consideration) to a willing buyer, taking into account all relevant factors determinative of value,
as determined jointly by the Board and NRV (without applying any marketability or other discounts). If such parties are unable
to reach agreement within a reasonable period of time, such fair value shall be determined (without applying any marketability
or other discounts) by an independent appraiser (other than one of the “Big Four” accounting firms) experienced in
valuing assets such as such consideration jointly selected by the Board and NRV. The determination of such appraiser shall be final
and binding upon the parties, and the Company shall pay the fees and expenses of such appraiser.

 

“Family Group”
shall mean, as to any particular Person, (i) such Person’s spouse and descendants
(whether natural or adopted); (ii) any trust solely for the benefit of such Person and/or such Person’s spouse and/or
descendants; and (iii) any partnerships, corporations or limited liability companies where the only partners, stockholders
or members are such Person and/or such Person’s spouse, descendants and/or trusts referred to in clause (ii) of this definition.

 

“Fundamental
Change” means (a) any sale, transfer or exclusive license of all or substantially all of the assets of the Company and
its Subsidiaries on a consolidated basis (measured either by book value in accordance with generally accepted accounting principles
consistently applied or by Fair Market Value determined in the good faith judgment of the Board) in any transaction or series of
transactions (other than sales of inventory and other sales in the ordinary course of business consistent with past practice),
(b) any merger or consolidation to which the Company is a party, except for (i) a merger or consolidation which is effected
solely to change the state of incorporation of the Company or (ii) a merger or consolidation in which the Company is the surviving
corporation, the terms and relative priorities of the Preferred Stock are not changed and the Preferred Stock is not exchanged
for cash, securities or other property, and after giving effect to such merger or consolidation, the holders of Common Stock and
the Series A Preferred Stock as of the effective time of the Merger (and after giving effect to the Merger) shall continue to own
more than 50% of the Company’s Common Stock (assuming conversion of the Series A Preferred Stock).

 

    	- 12 -

    	 

    

“License Agreement”
shall mean that certain Technology License and Services Agreement, dated as of October 31, 2012,
by and between Neurotrope, on the one hand, and BRNI and NRV II, on the other hand, as may be amended from time to time in accordance
with the terms thereof.

 

“Majority Abeles
Stockholders” shall mean, as of the date of any determination, the Abeles Stockholders
holding a majority of the Stockholder Shares then held by all Abeles Stockholders.

 

“Majority Common
Stockholders” shall mean, as of the date of any determination, the holders of Common
Stock holding a majority of the Stockholder Shares then held by all holders of Common Stock.

 

“Majority Stockholders”
shall mean, as of the date of any determination, the Stockholders holding a majority of the Stockholder
Shares then held by all Stockholders.

 

“Permitted Transferee”
shall mean (i) with respect to any Person who is an individual or a member of the Family
Group of an Executive, a member of such Person’s Family Group; and (ii) with respect to any Person which is an entity
(other than any Executive Stockholder or any other entity referred to in clause (i)), any of such Person’s Affiliates,
but only for so long as such Person remains a Permitted Transferee of such Person.

 

“Person”
shall mean an individual, a partnership, a corporation, a limited liability company, an association,
a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency
or political subdivision thereof.

 

“Pro Rata Basis”
shall mean, with respect to each Holder, and as determined with respect to any particular expense,
liability or obligation incurred (or amount of proceeds withheld) in connection with any Transfer of Equity Securities pursuant
to Section 4C or any Approved Sale, the amount such Holder’s proceeds would be reduced as a percentage of the
aggregate reduction in proceeds to applicable Holders assuming the Total Equity Value implied by such Transfer or Approved Sale
were being distributed in a liquidation, dissolution and winding up of the Corporation in accordance with the Certificate of Incorporation
in connection with such Transfer or Approved Sale and as if such expense, liability or obligation were incurred and satisfied (or
such amount of proceeds were withheld) prior to such distribution, as determined reasonably and in good faith by the Board.

 

“Pro Rata Share”
shall mean, with respect to each share of Series A Preferred Stock or Common Stock, the
proportionate amount such share would receive if an amount equal to the Total Equity Value were distributed in a liquidation, dissolution
and winding up of the Corporation in accordance with the Certificate of Incorporation, and with respect to each Stockholder, such
Stockholder’s proportionate share of the Total Equity Value based on the shares held by such Stockholder, in each case as
determined reasonably and in good faith by the Board.

 

    	- 13 -

    	 

    

“Public Offering”
shall mean any offering by the Company of its capital stock or equity securities to the public
pursuant to an effective registration statement under the Securities Act or any comparable statement under any similar federal
statute then in force.

 

“Public Sale”
shall mean any sale of Stockholder Shares to the public pursuant to an offering registered under
the Securities Act or to the public through a broker, dealer or market maker pursuant to the provisions of Rule 144 adopted under
the Securities Act (or any similar provision then in force).

 

“Qualified Public
Offering” shall mean a Public Offering underwritten on a firm commitment basis by a
nationally recognized investment bank in which (i) the aggregate proceeds received by the Company and any other selling stockholders
in such Public Offering (net of discounts, commissions and expenses) shall be at least $50,000,000; and (ii) the price per
share paid by the public for such shares will be an amount not less than $10 (as appropriately adjusted for stock splits, stock
combinations, stock dividends and the like with respect to the Common Stock).

 

“Securities
Act” shall mean the Securities Act of 1933, as amended, and applicable rules and regulations
thereunder, and any successor to such statute, rules or regulations.

 

“Stockholder
Shares” shall mean (i) any Common Stock purchased or otherwise acquired or held
by any Stockholder; (ii) any Common Stock issued or issuable directly or indirectly upon the conversion, exercise or exchange
of any securities purchased or otherwise acquired by any Stockholder which are convertible into or exercisable or exchangeable
directly or indirectly for Common Stock (including the Series A Preferred Stock but excluding options to purchase Common
Stock granted by the Company unless and until such options are exercised); and (iii) any other capital stock or equity securities
issued or issuable directly or indirectly with respect to the securities referred to in clauses (i) or (ii) above by way of a
stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other
reorganization. As to any particular securities constituting Stockholder Shares hereunder, such Stockholder Shares shall cease
to be Stockholder Shares hereunder when they have been (y) effectively registered under the Securities Act and disposed of
in accordance with the registration statement covering them or (z) sold to the public through a broker, dealer or market
maker pursuant to Rule 144 (or any similar provision then in force) under the Securities Act.

 

“Subsequent Financing”
shall mean the sale by the Company, after the completion of the A Round Financing (as such term
is defined in the License Agreement), of equity securities resulting in gross proceeds to the Company of not less than $12,000,000
(or such other amount as agreed by a unanimous vote of the Board).

 

“Subsidiary”
shall mean, with respect to any Person, any corporation, limited liability company, partnership,
association or other business entity of which (i) if a corporation, a majority of the total voting power of shares of stock entitled
(without regard to the occurrence of any contingency) to vote in the election of directors or trustees thereof is at the time owned
or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination thereof; or (ii)
if a limited liability company, partnership, association or other business entity, a majority of the limited liability company,
partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by that Person
or one or more Subsidiaries of that Person or a combination thereof. For purposes hereof, a Person or Persons shall be deemed to
have a majority ownership interest in a limited liability company, partnership, association or other business entity if such Person
or Persons shall be allocated a majority of the limited liability company, partnership, association or other business entity gains
or losses or shall be or control the managing member, general partner or managing director of such limited liability company, partnership,
association or other business entity.

 

    	- 14 -

    	 

    

“Total Equity
Value” shall mean the aggregate proceeds which would be received by the Stockholders
if: (i) the assets of the Company as a going concern were sold at their Fair Market Value; (ii) the Company satisfied
and paid in full all of its obligations and liabilities (including all taxes, costs and expenses incurred in connection with such
transaction and any reserves established by the Board for contingent liabilities); and (iii) such net sale proceeds were then
distributed in a liquidation, dissolution and winding up of the Corporation in accordance with the Certificate of Incorporation.
When determined in connection with a Fundamental Change or Change in Ownership, Total Equity Value shall be derived from the consideration
paid in connection with such Fundamental Change or Change in Ownership.

 

“Transfer”
shall mean any direct or indirect sale, transfer, assignment, pledge, mortgage, exchange, hypothecation,
grant of a security interest or other direct or indirect disposition or encumbrance of an interest (whether with or without consideration,
whether voluntarily or involuntarily or by operation of law) or the acts thereof or an offer or agreement to do the foregoing,
including issuances, but excluding conversions and redemptions of shares of capital stock or other Equity Securities by the Company
made in accordance with the Certificate of Incorporation. The terms “Transferee,” “Transferor,”
“Transferred,” and other forms of the word “Transfer” shall have the correlative meanings.

 

Section
8.    Transfers; Transfers in Violation of Agreement. Prior to Transferring any Stockholder Shares to any Person
or entity, the transferring Stockholder shall cause the prospective transferee to execute and deliver to the Company and the other
Stockholders a Joinder Agreement, substantially in the form of Exhibit A hereto. Any Transfer or attempted Transfer
of any Stockholder Shares in violation of any provision of this Agreement shall be void, and the Company shall not record such
Transfer on its books or treat any purported transferee of such Stockholder Shares as the owner of such Stockholder Shares for
any purpose.

 

Section
9.     Amendments and Waivers. Subject to Section 21, except as otherwise provided herein, the provisions
of this Agreement may be amended or waived only upon the prior written consent of the Company and Majority Stockholders;
provided that, no amendment, modification or waiver may be made with respect to Section 1, ‎2A,
‎Section 4, ‎Section 7, this ‎Section 9, Section 21
or Section 24 without the prior written consent of NRV; provided further that, no amendment, modification
or waiver may be made with respect to Section1, ‎Section 4, ‎Section 7,
this ‎Section 9, Section 21 or Section 24 without the prior written consent of the
Majority Abeles Stockholders; provided further that, for the avoidance of doubt, any amendment, modification
or waiver diminishing or adversely affecting the rights of any holder or group of holders of Stockholder Shares in a manner disproportionately
unfavorable to such holder or group of holders relative to the other holders or groups of holders of Stockholder Shares shall require
the prior written consent of the holder(s) of a majority of the Stockholder Shares so disproportionately unfavorably affected.
Each Stockholder agrees that any amendment, modification or waiver so approved shall be binding on such Stockholder, whether or
not such Stockholder provided such consent. The failure of any Party to enforce any of the provisions of this Agreement shall in
no way be construed as a waiver of such provisions and shall not affect the right of such Party thereafter to enforce each and
every provision of this Agreement in accordance with its terms.

 

    	- 15 -

    	 

    

Section
10.   Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable
law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability
of any other provision of this Agreement in such jurisdiction or affect the validity, legality or enforceability of any provision
in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid,
illegal or unenforceable provision had never been contained herein.

 

Section
11.  Entire
Agreement. This Agreement and the documents explicitly referred to herein contain the complete agreement between the parties
hereto with respect to the subject matter hereof and thereof and supersede any prior understandings, agreements and representations
by or between the parties hereto (whether written or oral) which may have related to the subject matter hereof or thereof in any
way.

 

Section 12.
    Successors and Assigns. Except as otherwise expressly provided herein, this Agreement shall bind and inure to
the benefit of and be enforceable by the Company and its successors and assigns and the Stockholders and any subsequent
holders of Stockholder Shares and the respective successors and assigns of each of them, so long as they hold Stockholder
Shares.

 

Section
13.  Counterparts.
This Agreement may be executed simultaneously in two or more counterparts (including by means of facsimile or electronic transmission
in portable document format (pdf)), any one of which need not contain the signatures of more than one party, but all such counterparts
taken together shall constitute one and the same Agreement.

 

Section
14.  Remedies.
The parties hereto shall be entitled to enforce their rights under this Agreement specifically, to recover damages by reason of
any breach of any provision of this Agreement and to exercise all other rights existing in their favor. The parties hereto agree
and acknowledge that money damages would not be an adequate remedy for any breach of the provisions of this Agreement and that
the Company and any Stockholder may in its sole discretion apply to any court of law or equity of competent jurisdiction for specific
performance and/or injunctive relief (without posting a bond or other security) in order to enforce or prevent any violation of
the provisions of this Agreement.

 

Section
15.  Notices.
All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall
be in writing and shall be deemed to have been given only (i) when delivered personally to the recipient, (ii) one (1)
business day after being sent to the recipient by reputable overnight courier service (charges prepaid) provided that confirmation
of delivery is received, (iii) upon machine-generated acknowledgment of receipt after transmittal by facsimile (provided that
a confirmation copy is sent via reputable overnight courier service for delivery within two (2) business days thereafter), or (iv) five
(5) after being mailed to the recipient by certified or registered mail (return receipt requested and postage prepaid). Such notices,
demands and other communications shall be sent to the Stockholders and to the Company at the addresses indicated below:

 

    	- 16 -

    	 

    

 

Notices to the Company:

 

Neurotrope BioScience, Inc.   

	Address:	10732 Hawk’s Vista St.
	 	Plantation, Florida 33324
	Attention:	Chief Executive Officer
	 	Jim New
	Telephone:	954-452-4656

 

 With a copy (which shall not constitute notice) to:

 

	Address:	Bilzin Sumberg Baena Price & Axelrod LLP
	 	1450 Brickell Avenue, 23rd Floor
	 	Miami, FL 33131
	Attention:	Laura Vaughn
	Telephone:	305-350-7282
	Facsimile: 	305-351-2286

Notices to BRNI:

 

Blanchette Rockefeller Neurosciences Institute  

	Address:	8 Medical Center Drive
	 	Morgantown, WV 26505-3409
	Attention:	Shana Phares
	 	Chief Executive Officer
	Telephone:	304-293-1361
	Facsimile:	304-293-7536

 

 

With a copy (which shall not constitute notice) to:

 

	Address:	Kirkland & Ellis, LLP
	 	300 North LaSalle
	 	Chicago, IL 60654
	Attention:	William Singer
	Telephone:	312-862-2142
	Facsimile:	312-862-2200

 

    	- 17 -

    	 

    

Notices to NRV:

 

Neuroscience Research Ventures, Inc.  

	Address:	364 Patteson Drive, #279
	 	Morgantown, WV  26505
	Attention: 	Tom Vorbach
	 	Assistant Secretary
	Telephone: 	304-598-8112

 

 

or to such other address or to the attention
of such other person as the recipient party has specified by prior written notice to the sending party.

 

Section
16.  Governing
Law. The corporate law of the State of Nevada shall govern all issues and questions concerning the relative rights and obligations
of the Company and its stockholders. All other issues and questions concerning the construction, validity, enforcement and interpretation
of this Agreement and the exhibits and schedules hereto shall be governed by, and construed in accordance with, the laws of the
State of Nevada, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Nevada
or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Nevada.

 

Section
17.   [Reserved].

 

Section
18.  Business
Days. If any time period for giving notice or taking action hereunder expires on a day which is a Saturday, Sunday or legal
holiday in the state in which the Company’s chief executive office is then located, the time period shall automatically be
extended to the business day immediately following such Saturday, Sunday or legal holiday.

 

Section
19.  Descriptive
Headings; Interpretation. The headings and captions used in this Agreement are for reference purposes only and shall not affect
in any way the meaning or interpretation of this Agreement. The use of the phrase “ordinary course of business” shall
mean “ordinary course of business consistent with past practice, including with respect to frequency and quantity.”
The use of the word “including” herein shall mean “including without limitation.” Any reference to the
masculine, feminine or neuter gender shall be deemed to include any gender or all three as appropriate. Any reference herein to
a holder of Stockholder Shares’ fully-diluted, as-if-converted ownership shall not include in the determination thereof any
shares of Common Stock issuable upon exercise of stock options issued pursuant to the Equity Incentive Plan.

 

Section
20.  No
Strict Construction. The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event
an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties,
and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions
of this Agreement. The Parties hereto intend that each covenant and agreement contained herein shall have independent significance.
If any party has breached any covenant or agreement contained herein in any respect, the fact that there exists another covenant
or agreement relating to the same subject matter (regardless of the relative levels of specificity) which such party has not breached
shall not detract from or mitigate the fact that such party is in breach of the first covenant or agreement.

 

    	- 18 -

    	 

    

Section 21.Termination.
Notwithstanding anything to the contrary contained herein, the Parties acknowledge and agree that this Agreement shall automatically
terminate and be of no further force and effect, without any further required action by any party, upon the termination of the
License Agreement; provided that, for the avoidance of doubt, the provisions of Section 24 shall only be deemed to
have terminated following completion of any actions required thereby.

 

Section 22.
 [Reserved].

 

Section 23. [Reserved].

 

Section 24.   Voting
Matters

 

24A. Voting Agreement
of Abeles Stockholders. Notwithstanding anything in this Agreement to the contrary, each Abeles Stockholder shall vote all
of his, her or its Stockholder Shares which are voting shares and any other voting securities of the Company over which such holder
has voting control, shall cause the Abeles Directors to vote or consent, as applicable, and shall take all other necessary or desirable
actions within his, her or its control (whether in his, her or its capacity as a stockholder, director, member of a board committee
or officer of the Company or otherwise, and including attendance at meetings in person or by proxy for purposes of obtaining a
quorum and execution of written consents in lieu of meetings), so that on each occasion that the board acts or proposes to act
(whether at a meeting or by written consent) with respect to (a) licensing or sublicensing of Licensed IP (as such term is defined
in the License Agreement), (b) a Fundamental Change or Change in Ownership or (c) the liquidation, dissolution or winding up of
the Company (any action described in clauses (a) through (c) of this sentence, a “Specified Board Action”):

 

(i)                
each Abeles Designee shall (a) vote or execute a written consent, as applicable, in favor of any Specified Board
Action approved (by vote or by execution of a written consent) by the NRV Designees and (b) vote against, or refrain from executing
a written consent in favor of, as applicable, any Specified Board Action not approved (by vote or by execution of a written consent)
by the NRV Designees; and

 

(ii)              
if a Specified Board Action is approved by the Board and submitted to the Company’s stockholders for approval,
each Abeles Stockholder shall vote all of his, her or its Stockholder Shares in favor of such Specified Board Action.

 

24B. Company Action.
The Company shall not take any action that is inconsistent with the provisions of this Section 24.

 

24C. Termination.
Subject to Section 21, the provisions of this Section 24 shall terminate automatically and shall be of
no further force and effect upon the first to occur of (a) the consummation of a Qualified Public Offering and (b) the closing
of the Company’s Subsequent Financing.

 

    	- 19 -

    	 

    

 

 

 

 

 

 

 

*****

 

 

 

 

 

 

 

 

 

    	- 20 -

    	 

    

IN WITNESS WHEREOF,
the Parties have executed or caused to be executed on their behalf this Stockholders Agreement as of the date first written above.

 

 

COMPANY:

 

NEUROTROPE, INC.

By:  /s/ Jim New                          

Name:Jim New

Its:President and Chief Executive Officer

 

    	 

    	 

    

IN WITNESS WHEREOF,
the Parties have executed or caused to be executed on their behalf this Stockholders Agreement as of the date first written above.

 

NRV:

 

NEUROSCIENCES RESEARCH

VENTURES, INC.

By:  /s/ William S. Singer                      

Name:William S. Singer

Its:Authorized Signatory

    	 

    	 

    

IN WITNESS WHEREOF,
the Parties have executed or caused to be executed on their behalf this Stockholders Agreement as of the date first written above.

 

ALKON:

/s/ Dan Alkon                               

Dan Alkon

    	 

    	 

    

IN WITNESS WHEREOF,
the Parties have executed or caused to be executed on their behalf this Stockholders Agreement as of the date first written above.

 

ABELES GROUP STOCKHOLDERS:

NORTHLEA PARTNERS LLLP

 

 

By: /s/ John Abeles                      

Name: John Abeles

Its: _______________________________

JIM NEW

 

 

/s/ Jim New                                     

    	 

    	 

    

SCHEDULE OF ABELES
GROUP STOCKHOLDERS

 

 

 

Northlea Partners LLLP

Jim New

 

    	 

    	 

    

JOINDER AGREEMENT

 

Effective upon the execution
hereof, the undersigned hereby agrees to become a party to and bound by that certain Stockholders Agreement, dated as of August
23, 2013, among Neurotrope, Inc., a Nevada corporation, and the other parties from time to time party thereto, as amended, modified
and waived from time to time (the “Stockholders Agreement”). The undersigned, by executing this joinder agreement,
shall be entitled to all of the rights and subject to all of the obligations of a Stockholder and a holder of Stockholder Shares
under the Stockholders Agreement.

 

 

Dated: __________, 20__

 

 

[ INVESTOR NAME ]

By:

Its:

 

By:

Its:

 

By:_________________________

Name:_________________________

Its:_________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]